Charles J. Yeo, MD, FACS

Charles J. Yeo, MD, FACS

Contact Dr. Yeo

1015 Walnut Street
Curtis Building, Suite 620
Philadelphia, PA 19107

(215) 955-8643
(215) 923-6609 fax

Most Recent Peer-reviewed Publications

  1. Total parenteral nutrition in patients following pancreaticoduodenectomy: lessons from 1184 patients
  2. Vascular Resections During the Whipple Procedure
  3. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells
  4. Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
  5. Pancreatic anastomosis after pancreatoduodenectomy: A position statement by the International Study Group of Pancreatic Surgery (ISGPS)
  6. Pneumonia is associated with a high risk of mortality after pancreaticoduodenectomy
  7. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
  8. Definition and classification of chyle leak after pancreatic operation: A consensus statement by the International Study Group on Pancreatic Surgery
  9. Invited commentary: Pasireotide and the prevention of pancreatic fistula after pancreatectomy "The continued search for Harry Potter's liquid luck"
  10. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma
  11. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial
  12. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
  13. Modified Appleby Procedure with Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma: A Literature Review and Report of Three Unusual Cases
  14. Hypothyroidism in Pancreatic Cancer: Role of Exogenous Thyroid Hormone in Tumor Invasion - Preliminary Observations
  15. Recurrence and survival after resection of small intraductal papillary mucinous neoplasm-associated Carcinomas (≤ 20-mm invasive component) A multi-institutional analysis
  16. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells
  17. Delayed Gastric Emptying After Pancreaticoduodenectomy: an Analysis of Risk Factors and Cost
  18. Fluid Restriction During Pancreaticoduodenectomy. Is It Effective in Reducing Postoperative Complications?
  19. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
  20. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs